Research programme: anti-infective mRNA therapeutics - ValeraAlternative Names: mRNA 1388; mRNA 1850; mRNA Therapeutics - Valera; mRNA Vaccines - Valera
Latest Information Update: 16 Sep 2016
At a glance
- Originator Moderna Therapeutics
- Developer Moderna Therapeutics; Valera LLC
- Class RNA; RNA vaccines
- Mechanism of Action Immunomodulators; Immunostimulants; Protein synthesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacterial infections; Infections; Parasitic infections; Viral infections; Zika virus infection
- Research HIV infections